The value of bispecific antibodies in relapsed and refractory DLBCL

References

• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–858. doi: 10.1056/NEJMra2027612
   PubMed Web of Science ®Google Scholar
• Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol. 2011;24(2):147–163. doi: 10.1016/j.beha.2011.02.006
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–2323. doi: 10.1056/NEJMoa0802885
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533–3537. doi: 10.1182/blood-2009-05-220095
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360–3365. doi: 10.1200/JCO.2009.26.3947
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e617. doi: 10.1016/S2352-3026(18)30177-7
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL rituximab-CHOP consortium program study. Blood. 2012;120(19):3986–3996. doi: 10.1182/blood-2012-05-433334
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2006;109(5):1857–1861. doi: 10.1182/blood-2006-08-038257
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842. doi: 10.1182/blood-2013-09-524108
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-Type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317–1328. doi: 10.1200/JCO.20.01366
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol. 2021;39(12):1329–1338. doi: 10.1200/JCO.20.01375
   PubMed Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in Non-Germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295. doi: 10.1200/JCO.18.02403
   PubMed Web of Science ®Google Scholar
• Verner E, Johnston A, Pati N, et al. Final analysis of Australasian leukaemia & lymphoma group NHL29: a phase II study of ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed DLBCL. Hematological Oncology. 2023;41(S2):426–427. doi: 10.1002/hon.3164_313
   Google Scholar
• Radhakrishnan VS, Stanton L, Caddy J, et al. Remodl-A: a randomised phase II evaluation of molecular guided therapy for diffuse large B-cell lymphoma (dlbcl) with acalabrutinib—ongoing trial. Hematological Oncology. 2023;41(S2):166–167. doi: 10.1002/hon.3163_T02
   Google Scholar
• Davies AJ, Barrans S, Stanton L, et al. Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up. J Clin Oncol. 2023;41(15):2718–2723. doi: 10.1200/JCO.23.00033
   PubMed Web of Science ®Google Scholar
• Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529–3537. doi: 10.1200/JCO.2017.73.3402
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung SH, et al. Dose-Adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799. doi: 10.1200/JCO.18.01994
   PubMed Web of Science ®Google Scholar
• Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–1867. doi: 10.1016/S0140-6736(11)61040-4
   PubMed Web of Science ®Google Scholar
• FDA US. FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma. FDA Press Release; 2023.
   Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi: 10.1182/blood-2017-03-769620
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190. doi: 10.1200/JCO.2010.28.1618
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–3496. doi: 10.1200/JCO.2013.53.9593
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545. doi: 10.1056/NEJM199512073332305
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2021;386(7):640–654. doi: 10.1056/NEJMoa2116133
   PubMed Web of Science ®Google Scholar
• Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675–1684. doi: 10.1182/blood.2022018730
   PubMed Web of Science ®Google Scholar
• Bishop MR, Dickinson M, Purtill D, et al. Second-Line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2021;386(7):629–639. doi: 10.1056/NEJMoa2116596
   PubMed Web of Science ®Google Scholar
• Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737–2746. doi: 10.1182/blood.2022015789
   PubMed Web of Science ®Google Scholar
• Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148–157. doi: 10.1056/NEJMoa2301665
   PubMed Web of Science ®Google Scholar
• FDA US. FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma; 2022.
   Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi: 10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018;380(1):45–56. doi: 10.1056/NEJMoa1804980
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi: 10.1016/S0140-6736(20)31366-0
   PubMed Web of Science ®Google Scholar
• Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–2221. doi: 10.1002/ijc.25423
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–4140. doi: 10.1200/JCO.2014.56.3247
   PubMed Web of Science ®Google Scholar
• Giri P, Patil S, Ratnasingam S, et al. Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2022;40(16_suppl):e19584–e19584. doi: 10.1200/JCO.2022.40.16_suppl.e19584
   Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi: 10.1038/s41573-019-0028-1
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838–847. doi: 10.1016/j.drudis.2015.02.008
   PubMed Web of Science ®Google Scholar
• Giese G, Williams A, Rodriguez M, et al. Bispecific antibody process development: assembly and purification of knob and hole bispecific antibodies. Biotechnol Prog. 2018;34(2):397–404. doi: 10.1002/btpr.2590
   PubMed Web of Science ®Google Scholar
• Ferl GZ, Reyes A, Sun LL, et al. A preclinical population pharmacokinetic model for anti-CD20/CD3 T-cell-dependent bispecific antibodies. Clin Transl Sci. 2018;11(3):296–304. doi: 10.1111/cts.12535
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. doi: 10.1056/NEJMoa011795
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7(5):379–391. doi: 10.1016/S1470-2045(06)70664-7
   PubMed Web of Science ®Google Scholar
• FDA US. FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. FDA. Online; 2022.
   Google Scholar
• FDA US. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. Online; 2023.
   Google Scholar
• FDA US. FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma. Online; 2023.
   Google Scholar
• Hawkes E, Lewis KL, Wong Doo N, et al. First-in-human (FIH) study of the fully-human Kappa-Lambda CD19/CD47 bispecific antibody TG-1801 in patients (pts) with B-cell lymphoma. Blood. 2022;140(Supplement 1):6599–6601. doi: 10.1182/blood-2022-169171
   Google Scholar
• Medicine USNLo. 2023 A Study of JNJ-75348780 in participants with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). <https://clinicaltrials.gov/study/NCT04540796?cond=NCT04540796&rank=1>.
   Google Scholar
• Herter S, Sam J, Ferrara Koller C, et al. RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB ligand combination with glofitamab as an off-the-shelf, enhanced T-cell redirection therapy for B-cell malignancies. Blood. 2020;136(Supplement 1):40–40. doi: 10.1182/blood-2020-134782
   Google Scholar
• Medicine USNLo. 2023 A study of JNJ-80948543, a T-cell redirecting CD79b x CD20 x CD3 Trispecific Antibody, in participants with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). <https://clinicaltrials.gov/study/NCT05424822?cond=NCT05424822&rank=1. >.
   Google Scholar
• Kim WS, Shortt J, Zinzani PL, et al. Abstract CT024: REDIRECT: a phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL). Cancer Research. 2023;83(8_Supplement): CT024–CT024. doi: 10.1158/1538-7445.AM2023-CT024
   Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi: 10.1182/blood-2014-05-552729
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. doi: 10.1016/j.bbmt.2018.12.758
   PubMed Web of Science ®Google Scholar
• Hosseini I, Gadkar K, Stefanich E, et al. Mitigating the risk of cytokine release syndrome in a phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020;6(1):28. doi: 10.1038/s41540-020-00145-7
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Sehn LH, Bartlett NL, et al. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal phase II study. Blood. 2023;142(Supplement 1):603–603. doi: 10.1182/blood-2023-173692
   Google Scholar
• Investigator Brochure Mosunetuzumab RO7030816 v8.0. 2022.
   Google Scholar
• Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2021;40(5):481–491. doi: 10.1200/JCO.21.00931
   PubMed Web of Science ®Google Scholar
• Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055–1065. doi: 10.1016/S1470-2045(22)00335-7
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Assouline S, Giri P, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2023;7(17):4926–4935. doi: 10.1182/bloodadvances.2022009260
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Avigdor A, Babu S, et al. Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma. Blood. 2022;140(Supplement 1):1778–1780. doi: 10.1182/blood-2022-157768
   Google Scholar
• Investigator Brochure Glofitamab RO7082859 v8.0. 2023.
   Google Scholar
• Bacac M, Colombetti S, Herter S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24(19):4785–4797. doi: 10.1158/1078-0432.CCR-18-0455
   PubMed Web of Science ®Google Scholar
• Dickinson M, Morschhauser F, Iacoboni G, et al. Cd20-tcb in relapsed or refractory non-hodgkin lymphoma: durable complete responses and manageable safety observed at clinically relevant doses in phase I dose escalation. European Hematology Association. Volume EHA library. Virtual; 2020.
   Google Scholar
• Hutchings M, Carlo-Stella C, Bachy E, et al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. Blood. 2020;136(Supplement 1):46–48. doi: 10.1182/blood-2020-136044
   Web of Science ®Google Scholar
• Carlo-Stella C, Hutchings M, Offner FC, et al. Glofitamab step-up dosing: updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-hodgkin lymphoma (nhl) patients. Hematological Oncology. 2021;39(S2). doi: 10.1002/hon.15_2879
   Google Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220–2231. doi: 10.1056/NEJMoa2206913
   PubMed Web of Science ®Google Scholar
• Hutchings M, Carlo-Stella C, Morschhauser F, et al. Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment. Blood. 2022;140(Supplement 1):1062–1064. doi: 10.1182/blood-2022-157554
   Google Scholar
• Ferhanoglu B, Gulbas Z, Uzay A, et al. Glofitamab in relapsed/refractory diffuse large B cell lymphoma: real world data. Blood. 2022;140(Supplement 1):6704–6705. doi: 10.1182/blood-2022-165385
   Google Scholar
• Hertzberg M, Ku M, Catalani O, et al. A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2021;39(15_suppl):TPS7575–TPS7575. doi: 10.1200/JCO.2021.39.15_suppl.TPS7575
   Web of Science ®Google Scholar
• Ghosh N, Townsend W, Dickinson M, et al. Glofitamab plus R-CHOP induces high response rates with minimal cytokine release syndrome (CRS) in patients (pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) and previously untreated (1L) diffuse large B-cell lymphoma (DLBCL): preliminary results from a dose-escalation and safety run-in phase Ib study. Blood. 2021;138(Supplement 1):2479–2479. doi: 10.1182/blood-2021-147780
   Google Scholar
• Hutchings M, Sureda A, Terol MJ, et al. Glofitamab (glofit) in combination with polatuzumab vedotin (pola): phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Blood. 2021;138(Supplement 1):525–525. doi: 10.1182/blood-2021-148359
   Google Scholar
• Minson A, Verner E, Giri P, et al. P1117: glofitamab plus R-chop or polatuzumab vedotin-R-chp is deliverable and yields high overall response in patients < =65 years of age with high-risk dlbcl or hgbl: interim analysis of the coalition study. HemaSphere. 2023;7(S3):e8608732. doi: 10.1097/01.HS9.0000971364.86087.32
   Google Scholar
• Dickinson M, Viardot A, Marks R, et al. Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase Ib study. J Clin Oncol. 2023;41(16_suppl):7549–7549. doi: 10.1200/JCO.2023.41.16_suppl.7549
   Web of Science ®Google Scholar
• Medicine USNLo. 2023 A study evaluating the efficacy, safety, and pharmacokinetics of Glofitamab in combination with rituximab plus Ifosfamide, carboplatin etoposide phosphate in participants with relapsed/refractory transplant or CAR-T therapy eligible diffuse B-cell lymphoma. <https://classic.clinicaltrials.gov/ct2/show/NCT05364424>.
   Google Scholar
• Medicine USNLo. 2023 A study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with other anti-cancer agents in participants with Relapsed or refractory B-cell non-Hodgkin lymphoma (LOTIS-7). <https://classic.clinicaltrials.gov/ct2/show/NCT04970901>.
   Google Scholar
• Hutchings M, Dickinson M, Carlo-Stella C, et al. Combining cd19-4-1bbl (ro7227166) with glofitamab is safe and shows early efficacy in patients suffering from relapsed or refractory B-cell non-hodgkin lymphoma. Hematological Oncology. 2023;41(S2):136–138. doi: 10.1002/hon.3163_91
   PubMedGoogle Scholar
• Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–2048. doi: 10.1182/blood.2019002729
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681–1690. doi: 10.1056/NEJMoa1301077
   PubMed Web of Science ®Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250–1259. doi: 10.1016/S1470-2045(12)70481-3
   PubMed Web of Science ®Google Scholar
• Investigator Brochure Epcoritamab. (DuoBody CD30xCD20) SUB-001397 v6.0. 2023.
   Google Scholar
• Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157–1169. doi: 10.1016/S0140-6736(21)00889-8
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2022;41(12):2238–2247. doi: 10.1200/JCO.22.01725
   PubMed Web of Science ®Google Scholar
• Kater AP, Ye JC, Sandoval-Sus J, et al. Subcutaneous epcoritamab in patients with richter’s syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). Blood. 2022;140(Supplement 1):850–851. doi: 10.1182/blood-2022-158298
   Google Scholar
• Eichhorst B, Eradat H, Niemann CU, et al. Epcoritamab monotherapy and combinations in relapsed or refractory chronic lymphocytic leukemia or richter’s syndrome: new escalation and expansion cohorts in epcore cll-1. Hematological Oncology. 2023;41(S2):828–829. doi: 10.1002/hon.3166_OT10
   PubMedGoogle Scholar
• Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20 × CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327–e339. doi: 10.1016/S2352-3026(22)00072-2
   PubMed Web of Science ®Google Scholar
• Kim W-S, Kim TM, Cho S-G, et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2. Blood. 2022;140(Supplement 1):1070–1071. doi: 10.1182/blood-2022-158406
   Google Scholar
• Hernandez GH, So J, Logronio KA, et al. Pharmacodynamics and biomarker correlates of imvotamab (IGM-2323), the first-in-class CD20xCD3 bispecific IgM antibody with dual mechanisms of action, in patients with advanced B cell malignancies. Blood. 2022;140(Supplement 1):6436–6438. doi: 10.1182/blood-2022-163235
   Google Scholar
• Nastoupil L, Budde E, Kim WS, et al. Abstract CT125: a phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas. Cancer Research. 2022;82(12_Supplement): CT125–CT125. doi: 10.1158/1538-7445.AM2022-CT125
   Google Scholar
• Cheah CY, Bartlett NL, Assouline S, et al. P1124: mosunetuzumab retreatment is effective and well-tolerated in patients with relapsed or refractory B-cell non-hodgkin lymphoma. HemaSphere. 2022;6:1014–1015. doi: 10.1097/01.HS9.0000847364.49527.45
   Google Scholar
• Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735–742. doi: 10.1038/s41591-022-01731-4
   PubMed Web of Science ®Google Scholar
• Falchi L, Clausen M, Offner F, et al. Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: updated EPCORE NHL-2 data. J Clin Oncol. 2023;41(16_suppl):7519–7519. doi: 10.1200/JCO.2023.41.16_suppl.7519
   Web of Science ®Google Scholar
• Topp MS, Tani M, Dickinson M, et al. Glofitamab plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase Ib study. Blood. 2022;140(Supplement 1):1775–1777. doi: 10.1182/blood-2022-157732
   Google Scholar